Lymphatic Diseases
Information
- Disease name
- Lymphatic Diseases
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02663297 | Active, not recruiting | Phase 1 | Administration of T Lymphocytes for Prevention of Relapse of Lymphomas | July 15, 2016 | January 2037 |
| NCT03264131 | Active, not recruiting | Phase 2 | BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma | October 15, 2018 | December 15, 2028 |
| NCT05441943 | Active, not recruiting | N/A | Lymphaticovenous Anastomosis as Treatment for Lymphedema | May 11, 2022 | December 31, 2026 |
| NCT03744676 | Completed | Phase 2 | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | November 29, 2018 | September 22, 2023 |
| NCT02497131 | Completed | Phase 2 | Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients | September 21, 2015 | March 2022 |
| NCT02744027 | Completed | N/A | Imaging of Lymphatic Anomalies | April 2016 | December 2017 |
| NCT02960841 | Completed | Phase 4 | Effectiveness of Intracavitary Manual Lymphatic Drainage | January 2012 | January 2016 |
| NCT03135535 | Completed | Phase 2 | Micro-mobile Foot Compression and Diabetic Foot | May 2, 2017 | May 14, 2021 |
| NCT02335242 | Completed | Phase 2 | Sildenafil for the Treatment of Lymphatic Malformations | May 23, 2015 | March 30, 2021 |
| NCT05683444 | Completed | Early Phase 1 | Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial | July 1, 2020 | March 26, 2021 |
| NCT03709407 | Completed | N/A | "Effects of Manual Lymphatic Drainage in the Neck in Healthy Subjects. Experimental Randomized Crossover Study" | June 1, 2018 | March 19, 2020 |
| NCT01451502 | Recruiting | N/A | Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units | October 20, 2011 | December 2025 |
| NCT02690545 | Recruiting | Phase 1/Phase 2 | Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL | August 26, 2016 | August 26, 2040 |
| NCT03602157 | Recruiting | Phase 1 | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | December 12, 2018 | September 30, 2041 |
| NCT03696784 | Recruiting | Phase 1 | Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | March 12, 2019 | March 22, 2043 |
| NCT05263583 | Recruiting | Phase 2 | Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma | December 9, 2022 | January 1, 2024 |
| NCT05731141 | Recruiting | A Prospective Natural History Study of Lymphatic Anomalies | March 20, 2023 | December 31, 2028 | |
| NCT06267807 | Recruiting | N/A | Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders | March 27, 2024 | June 1, 2025 |
| NCT02499627 | Terminated | Phase 2 | Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting | December 23, 2015 | June 30, 2020 |
| NCT03373019 | Unknown status | Phase 2 | Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | December 21, 2017 | March 1, 2021 |
| NCT05431179 | Withdrawn | Phase 3 | A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma | March 2023 | December 2026 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D008206